All the Active Ingredient Drugs
Protein L1 20 μg HPV 6 L1 protein, 40 μg HPV 11 L1 protein, 40 μg HPV 16 L1 protein, 20 μg HPV 18 ml 1 protein.. SYR. (susp. for inj.): 1 ×0.5 ml.
IM in deltoid/higher area of thigh.
Observe for 15 mins. aft. admin. As 3 separate doses.1st dose:electtd date,
2nd dose: 2 mnths. later, 3rd dose: 6
mnth. aft. 1st dose. Individ. 9 to and
includ. 13 yrs: can be admin. accord. to
a 2-dose schedule at 0, 6 mnths.
Females 9-45 yrs.: Prevent. cervical,
vulvar, vaginal cancer, precancer./
dysplast. lesions, genital warts, infect.
caused by Human Papillomavirus (HPV)
Types 6, 11, 16, and 18 (incl. in the
vaccine).See lit.
Males 16-26 yrs: Prevent. anal cancer,
precancer/dysplast. lesions, extern.
genital lesions and infect. caused by HPV
Types 6, 11, 16, and 18 (incl. in the
vaccine).See lit. Immunogencity studies
have been conduct. to link effic. in
females and males16-26 yrs to the
younger popultats.
C/I: Hypersens. to the act. subst./excip.
Individ. who develop sympt. indicative
of hypersens. aft. receiving a dose of
Gardasil. Admin. of Gardasil should be
postponed in individ. suffering from an
acute severe febrile illness. Presence of
a minor infect, such as a mild upper
resp. tract infect. or low-grade fever, is
not a C/I for immunisation. See lit.
